natgillin/translations-raw huggingface dataset:
whereby the nucleic acid molecule is selected from the group consisting of type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ.ID. 
gdje se molekulu nukleinske kiseline bira iz skupine koju čine molekule nukleinskih kiselina tipa A, molekule nukleinskih kiselina tipa B, molekule nukleinskih kiselina tipa C i molekule nukleinskih kiselina koje imaju nukleinskokiselinski slijed prema bilo kojem od SEQ.ID.
No. 57), and whereby the type C nucleic acid molecules comprise a core nucleotide sequence of GGUYAGGGCUHRXAAGUCGG (SEQ.ID. No. 90), whereby XA is either absent or is A. An L- nucleic acid molecule binding to SDF-1 for use in a method for depleting long-lived plasma cells, B cells and/or T cells from a subject, whereby the method comprises 
No. 57), i gdje molekule nukleinskih kiselina tipa C imaju osnovni nukleotidni slijed GGUYAGGGCUHRXAAGUCGG (SEQ.ID. No. 90), gdje je XA ili odsutan ili je A. Molekula L-nukleinske kiseline koja se veže na SDF-1 namijenjena upotrebi u postupku depletiranja dugoživućih plazmacita, B-stanica i/ili T-stanica iz subjekta, naznačena time što se postupak sastoji u
administering to the subject the nucleic acid molecule in an amount effective to mobilize said long-lived plasma cells, B cells and/or T cells into the peripheral blood of said subject; 
primjeni na subjektu molekule nukleinske kiseline u količini koja djelotvorno mobilizira navedene dugoživuće plazmacite, B-stanice i/ili T-stanice u perifernu krv navedenog subjekta;
An L- nucleic acid molecule binding to SDF-1 for use in therapy, wherein therapy comprises inhibiting the migration of leukocytes, whereby the nucleic acid molecule is selected from the group consisting of type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ.ID. 
Molekula L-nukleinske kiseline koja se veže na SDF-1 namijenjena upotrebi u terapiji, naznačena time što se terapija sastoji u inhibiranju migriranja leukocita, gdje se molekulu nukleinske kiseline bira iz skupine koju čine molekule nukleinskih kiselina tipa A, molekule nukleinskih kiselina tipa B, molekule nukleinskih kiselina tipa C i molekule nukleinskih kiselina koje imaju nukleinskokiselinski slijed prema bilo kojem od SEQ.ID.
No. 57), and whereby the type C nucleic acid molecules comprise a core nucleotide sequence of GGUYAGGGCUHRXAAGUCGG (SEQ.ID. No. 90), whereby XA is either absent or is A. The nucleic acid molecule for use according to claim 6, whereby, upon migration of the leukocytes, the leukocytes are accumulated in a tissue, whereby preferably the accumulation of the leukocytes leads to an inflammation in the tissue. 
No. 57), i gdje molekule nukleinskih kiselina tipa C imaju osnovni nukleotidni slijed GGUYAGGGCUHRXAAGUCGG (SEQ.ID. No. 90), gdje je XA ili odsutan ili je A. Molekula nukleinske kiseline namijenjena upotrebi u skladu s patentnim zahtjevom 6, naznačena time što se prilikom migriranja leukocita leukociti nakupljaju u tkivu, gdje po mogućnosti nakupljanje leukocita dovodi do upale u tkivu.
No. 57), and whereby the type C nucleic acid molecules comprise a core nucleotide sequence of GGUYAGGGCUHRXAAGUCGG (SEQ.ID. No. 90), whereby XA is either absent or is A. Use according to claim 8, wherein the L-nucleic acid molecule inhibits migration of leukocytes, dendritic cells and mast cells. 
No. 57), i gdje molekule nukleinskih kiselina tipa C imaju osnovni nukleotidni slijed GGUYAGGGCUHRXAAGUCGG (SEQ.ID. No. 90), gdje je XA ili odsutan ili je A. Upotreba u skladu s patentnim zahtjevom 8, naznačena time što molekula L-nukleinske kiseline inhibira migriranje leukocita, dendritičkih stanica i mastocita.
Use of an L-nucleic acid molecule binding to SDF-1 for the manufacture of a medicament for use in a method of treating and/or preventing a disease, wherein the method comprises inhibiting migration of leukocytes, whereby the nucleic acid molecule is selected from the group consisting of type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ.ID. 
Upotreba molekule L-nukleinske kiseline koja se veže na SDF-1, naznačena time što je molekula L-nukleinske kiseline namijenjena proizvodnji medikamenta namijenjenog upotrebi u postupku liječenja i/ili sprječavanja bolesti, gdje se postupak sastoji u inhibiranju migriranja leukocita, gdje se molekulu nukleinske kiseline bira iz skupine koju čine molekule nukleinskih kiselina tipa A, molekule nukleinskih kiselina tipa B, molekule nukleinskih kiselina tipa C i molekule nukleinskih kiselina koje imaju nukleinskokiselinski slijed prema bilo kojem od SEQ.ID.
Use of an L-nucleic acid molecule binding to SDF-1 for the manufacture of a medicament, whereby the medicament is for restoration or improvement of an immune system in a subject and whereby the nucleic acid molecule is selected from the group consisting of type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ.ID. 
Upotreba molekule L-nukleinske kiseline koja se veže na SDF-1, naznačena time što je molekula L-nukleinske kiseline namijenjena proizvodnji medikamenta, gdje je medikament namijenjen obnavljanju ili poboljšavanje imunosnog sustava kod subjekta i gdje se molekulu nukleinske kiseline bira iz skupine koju čine molekule nukleinskih kiselina tipa A, molekule nukleinskih kiselina tipa B, molekule nukleinskih kiselina tipa C i molekule nukleinskih kiselina koje imaju nukleinskokiselinski slijed prema bilo kojem od SEQ.ID.
Use of an L-nucleic acid molecule binding to SDF-1 for the manufacture of a medicament, whereby the medicament is for administration to a subject prior to or concomitant with chemotherapy, preferably chemotherapy administered for the treatment cancer, whereby the nucleic acid molecule is selected from the group consisting of type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ.ID. 
Upotreba molekule L-nukleinske kiseline koja se veže na SDF-1, naznačena time što je molekula L-nukleinske kiseline namijenjena proizvodnji medikamenta, gdje je medikament namijenjen primjeni na subjektu prije ili istodobno s kemoterapijom, po mogućnosti kemoterapijom koju se primjenjuje liječenju raka, gdje se molekulu nukleinske kiseline bira iz skupine koju čine molekule nukleinskih kiselina tipa A, molekule nukleinskih kiselina tipa B, molekule nukleinskih kiselina tipa C i molekule nukleinskih kiselina koje imaju nukleinskokiselinski slijed prema bilo kojem od SEQ.ID.
A process for preparing a compound of formula II wherein R1 is CN, CONH2, or COOR2, wherein R2 is C1-4 alkyl, comprising reacting a compound of formula V wherein R1 is CN, CONH2 or COOR2, wherein R2 is C1-4 alkyl, with the compound of formula IV at a temperature above 80°C without any solvent or in the presence of an amount of solvent up to 50 wt% of the sum of the weights of compounds V and IV, and in the presence of a salt added to the reaction mixture, wherein the salt is a lithium, sodium, potassium, rubidium, caesium, magnesium, calcium, strontium, barium, scandium, manganese, iron, copper, zinc, silver, boron, aluminium, gallium, indium, cerium, europium, ytterbium or bismuth salt. 
Postupak za pripravu spoja s formulom II naznačen time što R1 je CN, CONH2, ili COOR2, pri čemu R2 je C1-4 alkil, koji obuhvaća reakciju spoja s formulom V pri čemu R1 je CN, CONH2 ili COOR2, pri čemu R2 je C1-4 alkil, sa spojem s formulom IV pri temperaturi iznad 80°C bez ikakvog otapala ili u prisutnosti količine otapala do 50 tež.% zbroja težina spojeva V i IV, i u prisutnosti soli koja se dodaje u reakcijsku smjesu, pri čemu sol je litijeva, natrijeva, kalijeva, rubidijeva, cezijeva, magnezijeva, kalcijeva, stroncijeva, barijeva, skandijeva, manganova, željezova, bakrova, cinkova, srebrova, borova, aluminijeva, galijeva, indijeva, cerijeva, europijeva, iterbijeva ili bizmutova sol.
The process according to claim 1, wherein the amount of solvent is up to 20 wt% of the sum of the weights of the compounds of formula V and IV. 
Postupak prema patentnom zahtjevu 1, naznačen time što količina otapala iznosi do 20 tež.% zbroja težina spojeva formule V i IV.
The process according to any one of claims 1 to 6, wherein the salt is selected from lithium perchlorate, lithium trifluoromethanesulfonate, lithium bromide, lithium tifluoroacetate, lithium nitrate, lithium jodide, barium perchlorate, barium trifluoromethanesulfonate, calcium trifluoromethanesulfonate, or sodium trifluoromethanesulfonate. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je sol odabrana od litijevog perklorata, litijevog trifluorometansulfonata, litijevog bromida, litijevog tifluoroacetata, litijevog nitrata, litijevog jodida, barijevog perklorata, barijevog trifluorometansulfonata, kalcijevog trifluorometansulfonata, ili natrijevog trifluorometansulfonata.
The process according to claim 10, wherein the compound of formula II is converted into the compound of formula I by sequentially or simultaneously reducing the ketone and hydrolyzing the nitrile or the amide or the ester in R1 of the compound of formula II. 
Postupak prema patentnom zahtjevu 10, naznačen time što se spoj s formulom II pretvara u spoj s formulom I uzastopnom ili istodobnom redukcijom ketona i hidroliziranjem nitrila ili amida ili estera u R1 spoja s formulom II.
The process according to claim 11, wherein the compound of formula II is converted into the compound of formula I by simultaneously reducing the ketone and hydrolyzing the nitrile or the amide or the ester. 
Postupak prema patentnom zahtjevu 11, naznačen time što se spoj s formulom II pretvara u spoj s formulom I istodobnom redukcijom ketona i hidroliziranjem nitrila ili amida ili estera.
A composition for use according to claim 1, wherein the eicosapentaenoic acid ethyl ester comprises at least 96%, by weight, of all fatty acids present in the composition, the composition contains not more than 4% by weight, of total fatty acids other than eicosapentaenoic acid ethyl ester, and the composition contains about 0.1% to about 0.6% of at least one fatty acid other than eicosapentaenoic acid ethyl ester and docosahexaenoic acid. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što etilni ester ikozapentaenske kiseline sadrži najmanje 96%, težinski, od svih masnih kiselina prisutnih u pripravku, gdje pripravak sadrži najviše 4% težinski, od ukupnih masnih kiselina koje nisu etilni ester ikozapentaenske kiseline, te gdje pripravak sadrži otprilike 0,1% do otprilike 0,6% najmanje jedne masne kiseline koja nije etilni ester ikozapentaenske kiseline i dokozaheksaenska kiselina.
and R25 are taken together with the nitrogen to which they are attached to form a 4- to 7-membered monocyclic heterocycloalkyl group, or a 6- to 10-membered bicyclic heterocyclic group having fused, spiro, or bridged rings; L is 
i R25 se uzimaju zajedno sa azotom za koji su vezane, kako bi obrazovale monocikličnu heterocikloalkil grupu sa 4 do 7 članova, ili bicikličnu heterocikličnu grupu sa 6 do 10 članova koja ima kondenzirane, spiro, ili premošćene prstenove, i svaka R24 i R25 grupa može biti izborno supstituirana;
Ring Y is an optionally substituted pyridyl, pyrazole or thiadiazole; 
Prsten Y je po potrebi supstituirani piridil, pirazol ili tiadiazol;
A compound, or a physiologically acceptable salt thereof, for use according to claim 16, wherein the disorder is selected from Rheumatoid Arthritis, Psoriatic arthritis, Osteoarthritis, Systemic Lupus Erythematosus, Lupus nephritis, Ankylosing Spondylitis, Osteoporosis, Systemic sclerosis, Multiple Sclerosis, Psoriasis, Type I diabetes, Type II diabetes, Inflammatory Bowel Disease (Cronh's Disease and Ulcerative Colitis), Hyperimmunoglobulinemia D and periodic fever syndrome, Cryopyrin-associated periodic syndromes, Schnitzler's syndrome, Systemic juvenile idiopathic arthritis, Adult's onset Still's disease, Gout, Pseudogout, SAPHO syndrome, Castleman's disease, Sepsis, Stroke, Atherosclerosis, Celiac disease, DIRA (Deficiency of IL-1 Receptor Antagonist), Alzheimer's disease, Parkinson's disease, and Cancer. 
Spoj, ili njegova fiziološki prihvatljiva sol, za upotrebu prema zahtjevu 16, pri čemu je poremećaj odabran od reumatoidnog artritisa, psorijatičnog artritisa, osteoartritisa, sistemskog eritemskog lupusa, lupusnog nefritisa, ankilozirajućeg spondilitisa, osteoporoze, sistemske skleroze, multiple skleroze, psorijaze, dijabetesa tipa I, dijabetesa tipa II, upalne bolesti crijeva (Crohnova bolest i ulcerozni kolitis), hiperimunoglobulinemije D i sindroma periodične vrućice, periodičnih sindroma vezanih za kriopirin, Schnitzlerovog sindroma, sistemskog juvenilnog idiopatskog artritisa, Stillove bolesti odrasle dobi, gihta, pseudo gihta, SAPHO sindroma, Castlemanove bolesti, sepse, moždanog udara, ateroskleroze, celijakije, DIRA (nedostatka antagonista receptora IL-1), Alzheimerove bolesti, Parkinsonove bolesti, i raka.
A process for manufacturing a compound of formula I according to claim 1, comprising the steps of: reacting a compound of formula (A): with wherein X, Y, A, R, Ra, Rb, R2 and R3 are as defined in claim 1; to provide a compound of formula (B): 
Postupak za proizvodnju spoja formule I prema zahtjevu 1, naznačen time što sadrži korake: reakcija spoja formule (A): s pri čemu X, Y, A, R, Ra, Rb, R2 i R3 su kako je definirano u zahtjevu 1; da se dobije spoj s formulom (B):
A co-suspension for use according to claim 20, wherein the pulmonary disease or disorder is selected from at least one of asthma, COPD, exacerbation of airways hyper reactivity consequent to other drug therapy, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pulmonary hypertension, and pulmonary inflammation and obstruction associated with cystic fibrosis. 
Farmaceutski pripravak za uporabu prema patentnom zahtjevu 23, naznačen time što se plućna bolest ili poremećaj bira od najmanje jednog od astme, KOPB, kroničnog bronhitisa, emfizema, bronhiektazije, alergijskog rinitisa, sinusitisa, plućne vazokonstrikcije, upale, alergija, otežanog disanja, sindroma respiratornog distresa, plućne hipertenzije, upale pluća povezane s cističnom fibrozom, i opstrukcije pluća povezane s cističnom fibrozom.
A co-suspension for use according to claim 21 wherein the disease or disorder is COPD. 
Farmaceutski pripravak za uporabu prema patentnom zahtjevu 24 naznačen time što je bolest ili poremećaj KOPB.
A method of preparing a gypsum product comprising: 
Metodu pripreme cementnog proizvoda koja obuhvaća:
A method of detecting a target nucleic acid sequence in a sample comprising: 
Postupak detektiranja slijeda ciljane nukleinske kiseline u uzorku, naznačen time što se sastoji u:
an oligonucleotide probe sequence complementary to a region of a target nucleic acid sequence, wherein said oligonucleotide probe sequence has only one fluorophore label and which label is bound to an internal cytosine base and wherein said oligonucleotide probe sequence does not have a 3' end terminator, wherein the cytosine base is substantially centrally disposed along the oligonucleotide's length except for the positions 1-3 at the 3' end and the position 1 at the 5' end; and detecting the presence of the target nucleic acid, wherein an increases in fluorescence of the probe indicates the presence of the target nucleic acid in the sample. 
slijed oligonukleotidne sonde komplementaran području slijeda ciljane nukleinske kiseline, gdje navedeni slijed oligonukleotidne sonde ima samo jedan fluoroforni biljeg, gdje je navedeni biljeg vezan na unutarnju citozinsku bazu i gdje navedeni slijed oligonukleotidne sonde nema terminator na 3′ kraju, gdje se citozinska baza uglavnom nalazi u sredini po duljini oligonukleotida osim na položajima 1-3 na 3′ kraju i na položaju 1 na 5′ kraju; i detektiranju prisutnosti ciljane nukleinske kiseline, gdje pojačane fluorescencije sonde ukazuju na prisutnost ciljane nukleinske kiseline u uzorku.
The method of claim 1, wherein the oligonucleotide probe sequence is a DNA sequence and the target nucleic acid sequence is a DNA sequence. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je slijed oligonukleotidne sonde DNA slijed i slijed ciljane nukleinske kiseline je DNA slijed.
The method as claimed in claims 1-5, wherein the target nucleic acid is from a micro-organism, fungi, yeast or virus. 
Postupak u skladu s patentnih zahtjeva 1-5, naznačen time što je ciljana nukleinska kiselina iz mikroorganizma, gljive, kvasca ili virusa.
carrying out a method according to any one of claims 1-8; and detecting the presence of a nucleic acid derived from Chlamydia trachomatis and/or Neisseria gonorrhoeae, wherein an increase in the fluorescence of the probe indicates the presence of a Chlamydia trachomatis and/or Neisseria gonorrhoeae infection. 
provođenju postupka u skladu u skladu s bilo kojim od patentnih zahtjeva 1-8; i detektiranju prisutnosti nukleinske kiseline dobivene iz bakterije Chlamydia trachomatis i/ili bakterije Neisseria gonorrhoeae, gdje pojačanje fluorescencije sonde ukazuje na prisutnost zaraze bakterijom Chlamydia trachomatis i/ili bakterijom Neisseria gonorrhoeae.
The method of any preceding claim, wherein the probes are provided in a buffer system comprising dNTPs at a concentration of from 1-10mM, one or more salts at a concentration of each salt of from 2-20mM, Tris pH8.8 at a concentration of from 10-100mM, Trehalose at a concentration of from 10-100mM, BST polymerase at an amount of from 1U-12U and 0.01%-1% 1,2 propanediol. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što su sonde dodane u puferski sustav koji sadrži dNTP u koncentraciji od 1-10 mM, jednu ili više soli, gdje je koncentracija svake soli 2-20 mM, Tris pH 8,8 u koncentraciji od 10-100 mM, trehalozu u koncentraciji od 10-100 mM, BST-polimerazu u količini od 1 U-12 U i 0,01%-1% 1,2-propandiola.
The method of claim 12, wherein the one or more salts are selected from the group consisting of KCI, (NH4)2SO4 and MgSO4. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što se jednu ili više soli bira iz skupine koju čine KCl, (NH4)2SO4 i MgSO4.
The kit of claim 17, the one or more salts are selected from the group consisting of KCl, (NH4)2SO4 and MgSO4. 
Komplet u skladu s patentnim zahtjevom 17, naznačen time što se jednu ili više soli bira iz skupine koju čine KCl, (NH4)2SO4 i MgSO4.
The dosage form of claim 1 wherein said dosage form is a controlled release dosage form that releases in vitro 70 wt% of said apixaban over 2 hours or more after administration of said dosage form to an aqueous environment of use. 
Dozni oblik patentnog zahtjeva 1 gdje navedeni dozni oblik je dozni oblik sa kontroliranim oslobađanjem koji oslobađa in vitro 70 mas% navedenog apiksabana tokom 2 sata ili više nakon administriranja navedenog doznog oblika u vodenu sredinu primjene.
The dosage form of claim 1 wherein the controlled release dosage form is an osmotic controlled release dosage form. 
Dozni oblik patentnog zahtjeva 1 gdje dozni oblik sa kontroliranim oslobađanjem je dozni oblik sa osmotski kontroliranim oslobađanjem.
The dosage form of claim 3 wherein the controlled release dosage form is a bilayer osmotic controlled release dosage form. 
Dozni oblik patentnog zahtjeva 3 gdje dozni oblik sa kontroliranim oslobađanjem je dvoslojni dozni oblik sa osmotski kontroliranim oslobađanjem.
The dosage form of claim 8 wherein said solid amorphous dispersion is a spray-dried dispersion. 
Dozni oblik patentnog zahtjeva 8 gdje navedena čvrsta amorfna disperzija je disperzija sušena raspršivanjem.
The dosage form of claim 4 wherein said solid amorphous dispersion comprising said apixaban and the polymer is a spray-dried dispersion. 
Dozni oblik patentnog zahtjeva 4 gdje navedena čvrsta amorfna disperzija koja sadrži navedeni apiksaban i polimer je disperzija sušena raspršivanjem.
The dosage form of claim 1 wherein the controlled release dosage form is a matrix controlled release dosage form. 
Dozni oblik patentnog zahtjeva 1 gdje dozni oblik sa kontroliranim oslobađanjem je dozni oblik sa matričnim kontroliranim oslobađanjem.
The dosage form of claim 1 having an in-vitro dissolution rate, wherein the in-vitro dissolution rate is wherein less than about 10 wt% apixaban is released by one hour, about 20 wt% apixaban to about 40 wt% apixaban is released by four hours, about 60 wt% apixaban to about 80 wt% apixaban is released at about eight hours, and more than about 70 wt% apixaban is released at ten hours. 
Dozni oblik patentnog zahtjeva 1 koji ima in-vitro brzinu otapanja, gdje in-vitro brzina otapanja je gdje manje od oko 10 mas% apiksabana se oslobađa za jedan sat, oko 20 mas% apiksabana do oko 40 mas% apiksabana se oslobađa za četiri sata, oko 60 mas% apiksabana do oko 80 mas% apiksabana se oslobađa na oko osam sati, i više od oko 70 mas% apiksabana se oslobađa na deset sati.
The dosage form of claim 1 having an in-vitro dissolution rate, wherein the in-vitro dissolution rate is wherein less than about 20 wt% apixaban is released by one hour, about 20 wt% apixaban to about 40 wt% apixaban is released by two hours, about 50 wt% apixaban to about 75 wt% apixaban is released at about four hours, and more than about 70 wt% apixaban is released at six hours. 
Dozni oblik patentnog zahtjeva 1 koji ima in-vitro brzinu otapanja, gdje in-vitro brzina otapanja je gdje manje od oko 20 mas% apiksabana se oslobađa za jedan sat, oko 20 mas% apiksabana do oko 40 mas% apiksabana se oslobađa za dva sata, oko 50 mas% apiksabana do oko 75 mas% apiksabana se oslobađa na oko četiri sata, i više od oko 70 mas% apiksabana se oslobađa na šest sati.
The dosage form of any one of claims 1-11 for use in treating thromboembolic disorders. 
Dozni oblik bilo kog od patentnih zahtjeva 1-11 za primjenu u liječenju tromboemboličkih poremećaja.
The dosage form for use according to claim 12 wherein the thromboembolic disorder is venous thromboembolism, deep vein thrombosis, acute coronary syndrome or arterial thrombosis. 
Dozni oblik za primjenu prema patentnom zahtjevu 12 gdje tromboembolički poremećaj je venski tromboembolizam, tromboza dubokih vena, akutni koronarni sindrom ili arterijska tromboza.
wherein MAb is the antibody. 
[image] gdje MAb je protutijelo.
The composition according to claim 1, further comprising a chemical or biological pesticide, or a plant growth promoting agent. 
Spoj sukladno zahtjevu 1, koja dalje sadrži kemijski ili biološki pesticid ili sredstvo za poticanje rasta.
The method of claim 3, wherein the pest is a fungus or a bacterium. 
Postupak sukladno zahtjevu 3, naznačen time što je štetočina gljiva ili bakterija.
The method of claim 4, wherein the fungus is selected from the group consisting of Botrytis, Sclerotinia, Rhizotomies', and Bipolaris. 
Postupak sukladno zahtjevu 4, naznačen time što je bakterija odabrana iz skupine koju čine Bacillus, Ervinia, Acidovorak i Clavibacter.
The ligand binding molecule according to claim 1, wherein the ligand binding molecule consists of the amino acid sequence set forth in SEQ ID NO: 3. 
Molekula koji veže ligand sukladno patentnom zahtjevu 1, pri čemu se molekula koja veže ligand sastoji od aminokiselinske sekvence navedene u SEQ ID NO: 3.
An isolated cell or cell line transformed or transfected with a polynucleotide according to claim 3 or with a vector according to claim 4. 
Izolirana stanica ili stanična linija transformirana ili transficirana polinukleotidom sukladno patentnom zahtjevu 3 ili s vektorom sukladno patentnom zahtjevu 4.